These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 32590509)

  • 21. Drugs for allergic disorders.
    Treat Guidel Med Lett; 2010 Feb; 8(90):9-18; quiz 2 p following 18. PubMed ID: 20094023
    [No Abstract]   [Full Text] [Related]  

  • 22. Structural and clinical impact of anti-allergy agents: An overview.
    Kapoor Y; Kumar K
    Bioorg Chem; 2020 Jan; 94():103351. PubMed ID: 31668464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Allergic rhinitis: pathology of general interest].
    Incorvaia C; Barbera S; Makrì E; Mauro M
    Recenti Prog Med; 2013 Mar; 104(3):116-9. PubMed ID: 23548956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targets in allergy-directed immunotherapy.
    Verhagen J; Taylor A; Akdis M; Akdis CA
    Expert Opin Ther Targets; 2005 Apr; 9(2):217-24. PubMed ID: 15934911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction.
    Marple BF; Fornadley JA; Patel AA; Fineman SM; Fromer L; Krouse JH; Lanier BQ; Penna P;
    Otolaryngol Head Neck Surg; 2007 Jun; 136(6 Suppl):S107-24. PubMed ID: 17512862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents.
    Kimchi N; Bielory L
    Curr Opin Allergy Clin Immunol; 2020 Aug; 20(4):414-420. PubMed ID: 32558665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific immunotherapy and biological treatments for occupational allergy.
    Moscato G; Pala G; Sastre J
    Curr Opin Allergy Clin Immunol; 2014 Dec; 14(6):576-81. PubMed ID: 25115685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chinese guidelines for the diagnosis and treatment of allergic asthma (2019, the first edition)].
    ;
    Zhonghua Nei Ke Za Zhi; 2019 Sep; 58(9):636-655. PubMed ID: 31461815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allergy immunotherapy: the future of allergy treatment.
    Larsen JN; Broge L; Jacobi H
    Drug Discov Today; 2016 Jan; 21(1):26-37. PubMed ID: 26327511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence in immunotherapy for paediatric respiratory allergy: Advances and recommendations.
    Tortajada-Girbés M; Mesa Del Castillo M; Larramona H; Lucas JM; Álvaro M; Tabar AI; Jerez MJ; Martínez-Cañavate A;
    Allergol Immunopathol (Madr); 2016 Nov; 44 Suppl 1():1-32. PubMed ID: 27776895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current prospective of anti-IL-4, -IL-9, and -IL-13 therapies in allergic disease.
    Steinke JW
    Recent Pat Inflamm Allergy Drug Discov; 2010 Nov; 4(3):222-30. PubMed ID: 20807191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-IgE--emerging opportunities for Omalizumab.
    Babu KS; Polosa R; Morjaria JB
    Expert Opin Biol Ther; 2013 May; 13(5):765-77. PubMed ID: 23517576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Japanese guidelines for allergic rhinitis 2017.
    Okubo K; Kurono Y; Ichimura K; Enomoto T; Okamoto Y; Kawauchi H; Suzaki H; Fujieda S; Masuyama K;
    Allergol Int; 2017 Apr; 66(2):205-219. PubMed ID: 28214137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging drugs for the treatment of perennial allergic rhinitis.
    Licari A; Castagnoli R; Bottino C; Marseglia A; Marseglia G; Ciprandi G
    Expert Opin Emerg Drugs; 2016; 21(1):57-67. PubMed ID: 26733401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Allergic Rhinitis and its Impact on Asthma (ARIA) in Latin America].
    Baena-Cagnani CE
    Rev Alerg Mex; 2002; 49(6):181-8. PubMed ID: 12561650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omalizumab: not only for asthma.
    Ben-Shoshan M
    Recent Pat Inflamm Allergy Drug Discov; 2008 Nov; 2(3):191-201. PubMed ID: 19076009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost-effectiveness of immunotherapy for respiratory allergy: a review.
    Simoens S
    Allergy; 2012 Sep; 67(9):1087-105. PubMed ID: 22765521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of omalizumab in allergen immunotherapy.
    Dantzer JA; Wood RA
    Clin Exp Allergy; 2018 Mar; 48(3):232-240. PubMed ID: 29315922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [From evidence-based medicine to medicine-based evidence].
    González De Dios J
    An Esp Pediatr; 2001 Nov; 55(5):429-39. PubMed ID: 11696308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.